Feb 09, 2023
SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today
Nov 15, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe , Chief Executive
Oct 27, 2022
Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market SAN FRANCISCO --(BUSINESS WIRE)--Oct. 27, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company
Displaying 11 - 20 of 71